Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

Fischer, Monika; Kao, Dina; Kelly, Colleen R.; Kuchipudi, Aishwarya; Jafri, Syed Mohammed; Blumenkehl, Mark; Rex, Douglas K.; Mellow, Mark H.; Kaur, Nirmal; Sokol, Harry; Cook, G. K.; Hamilton, Matthew J.; Phelps, Emmalee; Sipe, Brian; Xu, Huiping; Allegretti, Jessica R.

doi:10.1097/mib.0000000000000908

Cited by 154 publications

(126 citation statements)

References 38 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…They compared post-FMT outcomes in these IBD patients to outcomes of non-IBD patients who had undergone FMT for the same indication, reporting that the failure rate after FMT did not differ between patients with and without IBD, which differs from other published experience in which patients with IBD fail FMT more frequently [9,11]. Furthermore, no complications secondary to FMT were reported, results in keeping with the published experience of other FMT centers [9,12].…”

contrasting

confidence: 31%

FMT in IBD: What Have We Learned?

Kelly

Allegretti

2017

Dig Dis Sci

Self Cite

View full text Add to dashboard Cite

contrasting

confidence: 31%

FMT in IBD: What Have We Learned?

Kelly

Allegretti

2017

Dig Dis Sci

Self Cite

View full text Add to dashboard Cite

“…Regimens have included vancomycin alone,12 14 18 35 39 55 59 86 117 metronidazole or vancomycin,40 41 43 122 or alternatively vancomycin, fidaxomicin or metronidazole,56 with one study using a range of regimens which included rifaximin 123. The length of treatment was also variable, ranging from 24 hours54 up to 4 days prior to receiving FMT39 45; however, comparative studies have not been undertaken.…”

Section: Rationale For Recommendationsmentioning

confidence: 99%

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Mullish

Quraishi

Segal

et al. 2018

Gut

255

171

View full text Add to dashboard Cite

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

show abstract

“…128 Similarly, a recent case series noted that 2.9% of patients treated for C. difficile who had underlying IBD required hospitalization for IBD flare after FMT. 129 This suggests that the potential for adverse effects in FMT may be greater in IBD than for recurrent C. difficile infection. In studies examining FMT for IBD without C. difficile infection, side effects are typically mild and self-limiting.…”

Section: Safety Of Fmtmentioning

confidence: 99%

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

2017

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a complex set of diseases that lead to chronic inflammation in the gastrointestinal tract. Although the etiology of IBD is not fully understood, it is well-known that the intestinal microbiota is associated with the development and maintenance of IBD. Manipulation of the gut microbiota, therefore, may represent a target for IBD therapy. Fecal microbiota transplantation (FMT), where fecal microbiota from a healthy donor is transplanted into a patient's GI tract, is already a successful therapy for Clostridium difficile infection. FMT is currently being explored as a potential therapy for IBD as well. In this review, the associations between the gut microbiota and IBD and the emerging data on FMT for IBD will be discussed.

show abstract

Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

Cited by 154 publications

References 38 publications

FMT in IBD: What Have We Learned?

FMT in IBD: What Have We Learned?

The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

Contact Info

Product

Resources

About